Hi Tony, I was further reflecting upon the comments by Virani, Global Head of Neuroscience Partnering at Roche and their search for collaborations in the field of autism spectrum disorders where there is high unmet need and evolving science; Virani particularly noted that Roche was interested in "programs that have shown some signal in related conditions such as Fragile X and Rett Syndrome". Its interesting to recap that Neuren recently presented at the Therapeutic Partnerships Conference.
Neuren had been chosen as one of the Top 10 Neuroscience projects by Windhover Conferences. Criteria for selection included "unmet medical need, market potential, diversity of applications, strong science, multi-level partnering opportunities, potential for new opportunities beyond initial indications and corporate stability." NNZ-2566 has certainly ticked a lot of boxes including the boxes identified by Virani. The 'potential for new opportunities beyond initial applications' is particularly valid noting your 'pipeline within a drug' assessment.
Neuren, in good time, will seek multi-level partnering opportunities. 2013 could be the year when the junior NZ biotech goes global.
NEU Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)